A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia.

INTRODUCTION: Long-term real-life data on the efficacy of dupilumab in atopic dermatitis (AD) patients, especially within the paediatric population, are limited. AIM: We aimed to evaluate in real life the effectiveness and safety of dupilumab in the treatment of adults and paediatric patients (6-17 years) with a special focus on the (hyper)eosinophilia trend during treatment. MATERIAL AND METHODS: A monocentric retrospective study was conducted at the Department of Dermatology, Venereology, and Allergology in Gdansk, Poland. RESULTS: A total of 70 patients were included, comprising 44 adults and 26 paediatric patients. In paediatric patients, Eczema Area and Severity Index (EASI) decreased by 86.65%, pruritus (P-NRS) by 72.40%, sleep disturbances (SD-NRS) by 73.44%, and Children's Dermatology Life Quality Index (cDLQI) by 76.82% at week (W) 52. In adults, EASI decreased by 95.66%, P-NRS by 79.66%, SD-NRS by 92.12%, and Dermatology Life Quality Index (DLQI) by 87.54% at W104. Among the paediatric patients, 17 experienced (hyper)eosinophilia at baseline (17/25, 68.0%), and 22 experienced (hyper)eosinophilia during the treatment period (22/26, 84.62%). Among adults, 24 experienced (hyper)eosinophilia at baseline (24/44, 54.55%), and 35 experienced (hyper)eosinophilia during the treatment period (35/44, 79.55%). No one discontinued treatment due to hypereosinophilia. CONCLUSIONS: Our results demonstrate that dupilumab is an effective and safe treatment for AD in both paediatric and adult populations in real-life settings, with significant and lasting improvements in disease severity and quality of life.